HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc... (ty Assay Kits and for its ContractResear...)

HOME >> BIOLOGY >> TECHNOLOGY

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services

Date:12/3/2008

ty Assay Kits and for its Contract Research Services using the HALO(R) Platform.

Ivan Rich, PhD, Founder and CEO of HemoGenix(R), said that, "It has been a pleasure working with ORF. Their response and products have been exceptional. Incorporating these growth factors and cytokines in our HALO(R) Platform products is extremely important for our quality control and potency assays, because we can now use biorisk- and contaminant-free products that provide far greater clinical relevance for the results that are obtained with our kits and services."

Bjorn Orvar, PhD, Co-founder and CEO of ORF Genetics, said that, "ORF Genetics ISOkine(TM) growth factors produced in our Orfeus(TM) plant-based production system are not only a novel approach for producing growth factors, but also a much-needed option for endotoxin-free, and animal- and serum-free components, for cell culture and medical research. HemoGenix(R) is a global leader of developing kits and assays for high throughput and validated cell- based assays for the detection and prediction of hemotoxicity, and we are very pleased to collaborate with HemoGenix(R) for the incorporation of our ISOkine(TM) growth factors and cytokines in its HALO(R) Hemotoxicity Assay Kits and Contract Research Services using the HALO(R) platform."

About HemoGenix(R), Inc

HemoGenix(R) was the first company in the world to provide high throughput and predictive cell-based in vitro assays to detect human hemotoxicity (toxicity to the blood-forming system). The HALO(R) Platform and other proprietary assays (LUMENESC(TM) and LumiSTEM(TM)) for different cell systems share the same ATP-based, in vitro bioluminescence technology. This allows biological responses to virtually any agent to be directly compared with each other across cell systems from different species simultaneously. Since its founding in 2000, HemoGenix(R) has developed its own portfolio of patented assays f
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease

Post Your Comments:

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc...(ty Assay Kits and for its ContractResear...)